Bleeding Academic Research Consortium

Jump to: navigation, search

Bleeding Microchapters

Home

Patient Information

Overview

Classification

Bleeding Academic Research Consortium
TIMI bleeding criteria
GUSTO bleeding criteria
CURE bleeding criteria
ACUITY HORIZONS bleeding criteria
STEEPLE bleeding criteria
PLATO bleeding criteria
GRACE bleeding criteria

Causes

Treatment

Emergency Bleeding Control

Reversal of Anticoagulation and Antiplatelet in Active Bleed

Perioperative Bleeding

Anemia Management
Coagulation Monitoring
Coagulation Management
Discontinuation, Bridging, and Reversal of Anticoagulation and Antiplatelet Therapy
Antiplatelet Agents
Heparin
Fondaparinux
Vitamin K Antagonists
New Oral Anticoagulants
Comorbidities Involving Hemostatic Derangement
Specific Surgeries
Cardiovascular Surgery
Gynecological Bleeding
Obstetric Bleeding
Orthopedic/Neurosurgery
Visceral/Transplant Surgery
Pediatric Surgery
Congenital Bleeding Disorders
von Willebrand Disease
Platelet Defects
Hemophilia A and B
Factor VII Deficiency
Rare Bleeding Disorders

Bleeding Academic Research Consortium On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bleeding Academic Research Consortium

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bleeding Academic Research Consortium

CDC on Bleeding Academic Research Consortium

Bleeding Academic Research Consortium in the news

Blogs on Bleeding Academic Research Consortium

Directions to Hospitals Treating Bleeding

Risk calculators and risk factors for Bleeding Academic Research Consortium

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

In order to harmonize and create a universal definition of bleeding, the Bleeding Academic Research Consortium (BARC) was convened. Dr. C Michael Gibson chaired the subcommittee drafting the definition of bleeding types 0, 1 and 2; Dr. Gabriel Stegg chaired the subcommittee drafting the definition of bleeding types 3a and 3b; Dr. Harvey White chaired the subcommittee drafting the definitions of coronary artery bypass grafting bleeding; and Dr. Deepak Bhatt chaired the subcommittee on fatal bleeding. The committee was chaired by Dr. Roxana Mehran and Dr. Sunil Rao.

BARC Definition (DO NOT EDIT)

Bleeding Academic Research Consortium (BARC) definition for Bleeding: [1]

Type 0:

Type 1:

  • Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a health-care professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health-care professional.

Type 2:

  • Any overt, actionable sign of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria:
  • requiring nonsurgical, medical intervention by a health-care professional,
  • leading to hospitalization or increased level of care, or
  • prompting evaluation

Type 3:

Type 3a:
  • Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL* (provided hemoglobin drop is related to bleed)
  • Any transfusion with overt bleeding
Type 3b:
Type 3c:
  • Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal),
  • Subcategories confirmed by autopsy or imaging or lumbar puncture,
  • Intraocular bleed compromising vision.

Type 4:

  • CABG-related bleeding,
  • Perioperative intracranial bleeding within 48 h,
  • Reoperation after closure of sternotomy for the purpose of controlling bleeding
  • Transfusion of ≥ 5 U whole blood or packed red blood cells within a 48-h period,
  • Chest tube output more than or equal to 2L within a 24-h period

Type 5:

  • Fatal bleeding
Type 5a:
  • Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious
Type 5b:
  • Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation

References

  1. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J; et al. (2011). "Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium.". Circulation. 123 (23): 2736–47. PMID 21670242. doi:10.1161/CIRCULATIONAHA.110.009449. 


Cardiology


Linked-in.jpg